Record Visits per Clinic per Day
Average visits per clinic per day reached a company record of 32.7 in Q2 2025, up from 30.6 in prior-year Q2 (≈+6.9%), with monthly averages of 33.0 (Apr), 32.9 (May) and 32.3 (Jun).
Physical Therapy Revenue Growth
Physical therapy revenue totaled $168.3M in Q2 2025, a $24.8M increase versus prior-year Q2 (+17.3%), driven largely by acquisitions (Metro contributed ~$19.6M of that growth).
Injury Prevention (IIP) Strong Performance
IIP net revenues increased $5.3M (+22.6% YoY); on an organic basis IIP revenues rose +18.4% and organic gross profit increased +21.8%. IIP margin expanded to 22.0% (from 21.4%).
Adjusted EBITDA and Margin Expansion
Q2 adjusted EBITDA was $26.9M, up $4.7M YoY. Adjusted EBITDA margin expanded to 17.5% from 16.4% in prior-year Q2.
Improved PT Gross Profit Margin and Cost Management
Physical therapy gross profit margin improved to 21.1% vs 20.1% in prior-year Q2. Salaries and related costs per visit were up only 0.7% (to $60.08) while total operating cost per visit decreased year over year.
Net Rate Stability and Commercial Pricing Lift
Net rate per patient visit was $105.33 in Q2 2025 (vs $105.05 in Q2 2024). Commercial rates increased ≈1.0%–1.5% YoY; workers’ comp remained >$150/visit and represented 10.4% of net patient revenues with visits +8.4% YoY.
Metro Acquisition Synergies
Post-acquisition rate improvement at Metro: initial month ~ $101 net rate, averaged $104.50 in Q1 and $107.50 in Q2, helping overall net rate and volume metrics (Metro averages ≈45 visits/clinic/day).
New Revenue Streams and Home Care Reporting
First-time separate reporting of home care visits (28,493 in Q2). Cash-based services rollout contributed ~ $900K incremental revenue in Q2 as the program ramps.
Raised Full-Year Guidance and Capital Actions
Full year 2025 adjusted EBITDA guidance was raised to $93M–$97M (from prior $88M–$93M). Board authorized a share repurchase program of up to $25M through 12/31/2026; acquisitions remain primary capital priority.
Balance Sheet and Interest Rate Management
Term loan balance $135M with an interest rate fixed at 4.7% via swap through mid-2027. Ended Q2 with $34.1M in cash.